Page last updated: 2024-09-04

vatalanib and Ascites

vatalanib has been researched along with Ascites in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fidler, IJ; Herrera, C; Killion, JJ; Wood, J; Xu, L; Yoneda, J	1

Other Studies

1 other study(ies) available for vatalanib and Ascites

Article	Year
Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. International journal of oncology, 2000, Volume: 16, Issue:3 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Ascites; Capillary Permeability; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured	2000

Article

Year

Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.

International journal of oncology, 2000, Volume: 16, Issue:3

Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Ascites; Capillary Permeability; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured

2000